MetaVia

MetaVia Liabilities

The The Liabilities of MetaVia (MTVA) as of Oct 30, 2026 is 63.79 M USD. In the previous year, The Liabilities was 8.33 M USD — a change of 665.88% (higher).

Liabilities

63.79 MUSD

YoY

665.88%

Last updated:

In 2025, MetaVia's total liabilities amounted to 63.79 M USD, a 665.88% difference from the 8.33 M USD total liabilities in the previous year.

The MetaVia Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
17.11 M USD
Jan 1, 2019
2.18 M USD
Jan 1, 2020
3.77 M USD
Jan 1, 2021
2.20 M USD
Jan 1, 2022
11.78 M USD
Jan 1, 2023
6.10 M USD
Jan 1, 2024
8.33 M USD
Jan 1, 2025
63.79 M USD
The MetaVia Liabilities history
YEARLiabilitiesYoY
63.79 MUSD+665.88%
8.33 MUSD+36.63%
6.10 MUSD-48.27%
11.78 MUSD+435.15%
2.20 MUSD-41.51%
3.77 MUSD+73.02%
2.18 MUSD-87.28%
17.11 MUSD+13.47%
15.08 MUSD+265.74%
4.12 MUSD-75.57%
16.87 MUSD+1,819.23%
879,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing MetaVia's Liabilities

MetaVia's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating MetaVia's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing MetaVia's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

MetaVia's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in MetaVia’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about MetaVia stock

The Liabilities of MetaVia is 63.79 M USD in 2025.

The Liabilities of MetaVia changed from 8.33 M USD to 63.79 M USD, representing a 665.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities MetaVia since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's MetaVia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MetaVia

All Key Metrics — MetaVia